Cell-Based Assay Development and Standardization for Antibody-Drug Conjugates.
- 1Large Molecule Analytical, Merck & Co., Inc., 126 East Lincoln Avenue, Rahway, NJ 07065, USA.
- 2Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd., 666 Xinhua Avenue, Wenjiang District, Chengdu 611138, China.
- 3Department of Process Research and Development, Merck & Co., Inc., 126 East Lincoln Avenue, Rahway, NJ 07065, USA.
Abstract
ADC-111 is an Antigen-1-targeting antibody-drug conjugate with approximately eight payloads conjugated to one monoclonal antibody. The primary mechanism of action of ADC-111 is payload-induced cytotoxicity after antigen-antibody binding-mediated internalization. A cell-based assay using T24 cells engineered with Antigen-1 expression was developed and phase-appropriately validated to measure the potency of ADC-111 drug substance and drug product. This specific and stability-indicating assay detected potency loss resulting from degradation in the complementarity-determining region of the antibody, and correlated closely with the results from the Antigen-1 binding enzyme-linked immunosorbent assay, demonstrating that the ADC-111 cell-based assay is antigen-binding dependent. The potency measured by the cell-based assay also showed good correlation with varying drug-antibody ratio values, but ELISA did not. Notably, the ready-to-use format of the cell-based assay had performance comparable to that of the continuous culture using the same procedure, allowing both formats to be used interchangeably. In addition, the same parental cell line T24 was engineered with other tumor antigens, and the corresponding cell-based assay also showed good specificity, demonstrating the proof-of-concept of using a single parental cell line for multiple ADCs to standardize and accelerate cell-based assay development.
Related
- Efficacy and safety of antibody-drug conjugates in advanced small cell lung cancer: a systematic review and single-arm meta-analysis of prospective clinical trials
- Antibody‒cell conjugates: A novel "off-the-shelf" modality bridging ADCs and CAR-T for cancer immunotherapy.
- Antibody–drug conjugates and immunogenic cell death in breast cancer: agent-specific mechanisms, clinical evidence and translational priorities
- Antigen persistence after antibody-drug conjugates in urothelial carcinoma: implications for CAR-cell target selection
- Intracranial Activity of Deruxtecan-Based Antibody–Drug Conjugates in Non-Small Cell Lung Cancer Brain Metastases: A Systematic Review and Meta-Analysis of Prospective Trial Cohorts
BibTeX
@article{sun2026cellbased,
title = {{Cell-Based Assay Development and Standardization for Antibody-Drug Conjugates.}},
author = {Dengyun Sun and Amy Hsu and Hu Long and Ke Qin and Jonathan Welch and Scott McCann and Zhijie Jey Cheng},
journal = {Biotech (Basel (Switzerland))},
year = {2026},
month = oct,
doi = {10.3390/biotech15040096},
url = {https://europepmc.org/article/MED/42930073},
note = {CC BY},
}
RIS
TY - JOUR
TI - Cell-Based Assay Development and Standardization for Antibody-Drug Conjugates.
AU - Dengyun Sun
AU - Amy Hsu
AU - Hu Long
AU - Ke Qin
AU - Jonathan Welch
AU - Scott McCann
AU - Zhijie Jey Cheng
PY - 2026
DA - 2026/10/20
JO - Biotech (Basel (Switzerland))
DO - 10.3390/biotech15040096
UR - https://europepmc.org/article/MED/42930073
AB - ADC-111 is an Antigen-1-targeting antibody-drug conjugate with approximately eight payloads conjugated to one monoclonal antibody. The primary mechanism of action of ADC-111 is payload-induced cytotoxicity after antigen-antibody binding-mediated internalization. A cell-based assay using T24 cells engineered with Antigen-1 expression was developed and phase-appropriately validated to measure the potency of ADC-111 drug substance and drug product. This specific and stability-indicating assay detected potency loss resulting from degradation in the complementarity-determining region of the antibody, and correlated closely with the results from the Antigen-1 binding enzyme-linked immunosorbent assay, demonstrating that the ADC-111 cell-based assay is antigen-binding dependent. The potency measured by the cell-based assay also showed good correlation with varying drug-antibody ratio values, but ELISA did not. Notably, the ready-to-use format of the cell-based assay had performance comparable to that of the continuous culture using the same procedure, allowing both formats to be used interchangeably. In addition, the same parental cell line T24 was engineered with other tumor antigens, and the corresponding cell-based assay also showed good specificity, demonstrating the proof-of-concept of using a single parental cell line for multiple ADCs to standardize and accelerate cell-based assay development.
SN - 2673-6284
ER -